Written by Private MD Labs Medical Writing Team ⢠Last Updated: September 8, 2025
Non-Hodgkin's lymphoma (NHL) is a cancer that begins in the lymphatic system and is typically diagnosed through tissue biopsy and imaging studies. While there is no single blood test to diagnose NHL itself, blood testing plays a fundamental role in monitoring the body's response to the cancer, detecting protein abnormalities, and assessing for related complications or risk factors.
This test analyzes the different types of proteins in the blood and can detect abnormal protein production caused by Non-Hodgkin's lymphoma. The electrophoresis component separates proteins to identify unusual patterns that may indicate lymphoma cell activity.
Non-Hodgkin's lymphoma affects the immune system and can cause various biochemical changes in the blood. Testing helps healthcare providers monitor disease progression, assess immune system activation, detect abnormal protein production by lymphoma cells, and identify underlying infections that may increase lymphoma risk. These tests are essential for comprehensive patient management and treatment planning.
Non-Hodgkin's lymphoma cells can produce excess amounts of light chain proteins. This test measures these specific proteins in the blood, as abnormal levels can indicate lymphoma cell proliferation and help monitor disease activity.
This test measures a marker of T-cell activation in the blood. Non-Hodgkin's lymphoma often involves increased immune system activation, and elevated IL-2Ra/CD25 levels can indicate heightened lymphoma-related immune activity.
Chronic Hepatitis C infection significantly increases the risk of developing Non-Hodgkin's lymphoma. This test detects active Hepatitis C infection, which is important for risk assessment and management in NHL patients.
The information here is for educational purposes only and is not a substitute for professional medical advice. Always consult with a healthcare provider for diagnosis and treatment. These blood tests support the overall management of Non-Hodgkin's lymphoma but cannot replace tissue biopsy for definitive diagnosis.